Chicago Capital LLC Purchases 3,551 Shares of ResMed Inc. (NYSE:RMD)

Chicago Capital LLC increased its holdings in shares of ResMed Inc. (NYSE:RMD - Free Report) by 24.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,251 shares of the medical equipment provider's stock after purchasing an additional 3,551 shares during the period. Chicago Capital LLC's holdings in ResMed were worth $4,174,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Geode Capital Management LLC raised its stake in shares of ResMed by 10.9% in the 3rd quarter. Geode Capital Management LLC now owns 3,858,814 shares of the medical equipment provider's stock valued at $939,114,000 after purchasing an additional 380,383 shares during the period. Caisse DE Depot ET Placement DU Quebec raised its position in ResMed by 726.3% in the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 283,801 shares of the medical equipment provider's stock valued at $69,281,000 after buying an additional 249,454 shares during the last quarter. Nordea Investment Management AB lifted its stake in ResMed by 92.7% in the 4th quarter. Nordea Investment Management AB now owns 448,151 shares of the medical equipment provider's stock valued at $103,214,000 after acquiring an additional 215,561 shares in the last quarter. State Street Corp boosted its position in ResMed by 1.9% during the 3rd quarter. State Street Corp now owns 6,261,633 shares of the medical equipment provider's stock worth $1,528,590,000 after acquiring an additional 116,918 shares during the last quarter. Finally, Tidal Investments LLC grew its stake in shares of ResMed by 738.4% during the 3rd quarter. Tidal Investments LLC now owns 104,938 shares of the medical equipment provider's stock worth $25,617,000 after acquiring an additional 92,422 shares in the last quarter. 54.98% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at ResMed

In other ResMed news, Director Peter C. Farrell sold 2,000 shares of the stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $242.11, for a total transaction of $484,220.00. Following the transaction, the director now owns 77,218 shares in the company, valued at $18,695,249.98. This trade represents a 2.52 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Witte Jan De sold 796 shares of ResMed stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $248.81, for a total value of $198,052.76. Following the sale, the director now directly owns 6,723 shares of the company's stock, valued at $1,672,749.63. This represents a 10.59 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 11,094 shares of company stock valued at $2,704,941 in the last three months. 0.71% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the stock. Needham & Company LLC reissued a "hold" rating on shares of ResMed in a research report on Friday, January 31st. The Goldman Sachs Group initiated coverage on shares of ResMed in a research report on Thursday, January 16th. They set a "buy" rating on the stock. UBS Group upgraded ResMed from a "hold" rating to a "strong-buy" rating in a report on Friday, January 31st. StockNews.com upgraded ResMed from a "hold" rating to a "buy" rating in a report on Tuesday, October 15th. Finally, Stifel Nicolaus began coverage on ResMed in a research report on Friday, December 13th. They set a "hold" rating and a $250.00 price target for the company. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, ResMed currently has an average rating of "Moderate Buy" and an average price target of $244.73.

ResMed Stock Performance

Shares of NYSE RMD traded down $5.47 during midday trading on Thursday, hitting $237.11. 992,644 shares of the company's stock were exchanged, compared to its average volume of 1,030,356. The company has a quick ratio of 2.29, a current ratio of 3.33 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $34.81 billion, a PE ratio of 27.99, a price-to-earnings-growth ratio of 1.69 and a beta of 0.70. ResMed Inc. has a 12 month low of $170.56 and a 12 month high of $263.05. The company's 50 day moving average price is $239.68 and its 200 day moving average price is $237.19.

ResMed (NYSE:RMD - Get Free Report) last released its quarterly earnings data on Thursday, January 30th. The medical equipment provider reported $2.43 EPS for the quarter, topping analysts' consensus estimates of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%. As a group, analysts predict that ResMed Inc. will post 9.41 earnings per share for the current fiscal year.

ResMed Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 13th will be paid a $0.53 dividend. The ex-dividend date of this dividend is Thursday, February 13th. This represents a $2.12 dividend on an annualized basis and a yield of 0.89%. ResMed's dividend payout ratio (DPR) is currently 25.03%.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.